RVMD Revolution Medicines

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.

The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click . An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website at for at least 14 days following the live event.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.



Media & Investor Contacts:
EN
27/11/2024

Underlying

RVMDRevolution Medicines

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Revolution Medicines

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
INC
08/08/25 August 8, 2025 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
BKNG BOOKING HOLDINGS INC.
RCUS ARCUS BIOSCIENCES
UBER UBER TECHNOLOGIES INC.
DT DYNATRACE INC.
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
STX SEAGATE TECHNOLOGY HLDGS PLC
APP APPLOVIN CORP
YOU CLEAR SECURE INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
08/07/25 August 7, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
RVMD REVOLUTION MEDICINES
08/06/25 August 6, 2025 1 EN
 PRESS RELEASE
Free
RVMD Revolution Medi...

Revolution Medicines Reports Second Quarter 2025 Financial Results and...

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Ti...

August 6, 2025 1 EN
Wedbush Research
  • Wedbush Research
GEO GEO GROUP INC. (THE)
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
CVCO CAVCO INDUSTRIES INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
HEAR TURTLE BEACH CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ARVN ARVINAS HOLDING
SMCI SUPER MICRO COMPUTER
RVMD INC.
CRSR REVOLUTION MEDICINES
PRAX CORSAIR GAMING
TVTX PRAXIS PRECISION MEDICINES
PLTK TRAVERE THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
DAWN NUVATION BIO INC (A)
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
GFS INC
SKLZ SEAGATE TECHNOLOGY HLDGS PLC
CBIO GLOBALFOUNDRIES INC
SKILLZ INC
CRESCENT BIOPHARMA INC.
08/04/25 August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch